Description

This Drug Discovery TOE provides insights across in vivo, in vitro, and in silico assay technologies enabling enhanced drug discovery across the European region. The service encompasses innovations across microfluidics, artificial cells, predictive modeling, phenotypic assays, screening, iPSC, cell culture, scaffold, and proteome platform technologies for drug discovery and screening applications. Additionally, this TOE encompasses clinical trials for migraine prevention.

The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.

The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Drug discovery and development, 3D micropatterning, microfluidic, biomimetic, organ-on-a-chip, artificial cells, optical laser, predictive modeling, simulation, iPSC, phenotypic assay, compound screening, cell culture, migraine